Search

Your search keyword '"Schreuder, Floris H. B. M."' showing total 11 results
Start Over Author "Schreuder, Floris H. B. M." Publisher biomed central
11 results on '"Schreuder, Floris H. B. M."'

8. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

Author

Marazuela, Paula, Solé, Montse, Bonaterra-Pastra, Anna, Pizarro, Jesús, Camacho, Jessica, Martínez-Sáez, Elena, Kuiperij, H. Bea, Verbeek, Marcel M., de Kort, Anna M., Schreuder, Floris H. B. M., Klijn, Catharina J. M., Castillo-Ribelles, Laura, Pancorbo, Olalla, Rodríguez-Luna, David, Pujadas, Francesc, Delgado, Pilar, and Hernández-Guillamon, Mar

Published
2021
Full Text
View/download PDF

10. Microvasculature and intraplaque hemorrhage in atherosclerotic carotid lesions: a cardiovascular magnetic resonance imaging study

Author

Crombag, Geneviève A. J. C., Schreuder, Floris H. B. M., van Hoof, Raf H. M., Truijman, Martine T. B., Wijnen, Nicky J. A., Vöö, Stefan A., Nelemans, Patty J., Heeneman, Sylvia, Nederkoorn, Paul J., Daemen, Jan-Willem H., Daemen, Mat J. A. P., Mess, Werner H., Wildberger, J. E., van Oostenbrugge, Robert J., and Kooi, M. Eline

Published
2019
Full Text
View/download PDF

11. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.

Author

de Kort, Anna M., Kuiperij, H. Bea, Jäkel, Lieke, Kersten, Iris, Rasing, Ingeborg, van Etten, Ellis S., van Rooden, Sanneke, van Osch, Matthias J. P., Wermer, Marieke J. H., Terwindt, Gisela M., Schreuder, Floris H. B. M., Klijn, Catharina J. M., and Verbeek, Marcel M.

Subjects
CEREBRAL amyloid angiopathy, AMYLOID, BIOMARKERS
Abstract

Background: The diagnosis of probable cerebral amyloid angiopathy (CAA) is currently mostly based on characteristics of brain MRI. Blood biomarkers would be a cost-effective, easily accessible diagnostic method that may complement diagnosis by MRI and aid in monitoring disease progression. We studied the diagnostic potential of plasma Aβ38, Aβ40, and Aβ42 in patients with hereditary Dutch-type CAA (D-CAA) and sporadic CAA (sCAA). Methods: All Aβ peptides were quantified in the plasma by immunoassays in a discovery cohort (11 patients with presymptomatic D-CAA and 24 patients with symptomatic D-CAA, and 16 and 24 matched controls, respectively) and an independent validation cohort (54 patients with D-CAA, 26 presymptomatic and 28 symptomatic, and 39 and 46 matched controls, respectively). In addition, peptides were quantified in the plasma in a group of 61 patients with sCAA and 42 matched controls. We compared Aβ peptide levels between patients and controls using linear regression adjusting for age and sex. Results: In the discovery cohort, we found significantly decreased levels of all Aβ peptides in patients with presymptomatic D-CAA (Aβ38: p < 0.001; Aβ40: p = 0.009; Aβ42: p < 0.001) and patients with symptomatic D-CAA (Aβ38: p < 0.001; Aβ40: p = 0.01; Aβ42: p < 0.001) compared with controls. In contrast, in the validation cohort, plasma Aβ38, Aβ40, and Aβ42 were similar in patients with presymptomatic D-CAA and controls (Aβ38: p = 0.18; Aβ40: p = 0.28; Aβ42: p = 0.63). In patients with symptomatic D-CAA and controls, plasma Aβ38 and Aβ40 were similar (Aβ38: p = 0.14; Aβ40: p = 0.38), whereas plasma Aβ42 was significantly decreased in patients with symptomatic D-CAA (p = 0.033). Plasma Aβ38, Aβ40, and Aβ42 levels were similar in patients with sCAA and controls (Aβ38: p = 0.092; Aβ40: p = 0.64. Aβ42: p = 0.68). Conclusions: Plasma Aβ42 levels, but not plasma Aβ38 and Aβ40, may be used as a biomarker for patients with symptomatic D-CAA. In contrast, plasma Aβ38, Aβ40, and Aβ42 levels do not appear to be applicable as a biomarker in patients with sCAA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results